Literature DB >> 10573533

Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure.

S Miwa1, Y Hashikura, A Mita, T Kubota, H Chisuwa, Y Nakazawa, T Ikegami, M Terada, S Miyagawa, S Kawasaki.   

Abstract

The prognosis for patients with fulminant (FHF) or subfulminant hepatic failure (SFHF) has improved since the introduction of liver transplantation. However, the death rate of patients awaiting liver transplantation is high, possibly because of the difficulty in obtaining grafts in a timely manner, given the relative shortage of cadaveric donors. Between June 1990 and June 1999, 106 patients underwent living-related liver transplantation (LRLT) at Shinshu University Hospital. Among them, 8 patients had FHF and 6 had SFHF; these 14 patients are the subjects of this report. The graft volumes (GV) ranged from 231 mL to 625 mL, corresponding to 35% to 105% of the recipients' standard liver volume (SLV). The postoperative courses of all donors were uneventful. Following liver transplantation, all grafts functioned favorably, with normalization of serum total bilirubin within 3 to 5 days and normalization of coagulation profiles within 4 to 7 days. Thirteen of the 14 recipients are still alive. The actuarial 6-month, 1-year, and 5-year survival rates were 100%, 90%, and 90%, respectively. In the present study, when the ratio of the GV to the recipient's SLV was more than 35%, the graft was able to support the patient's metabolic demand after liver transplantation for FHF or SFHF. Because of the urgent nature of liver transplantation in this clinical condition, concerns over informed consent may be even greater than for elective LRLT. Nevertheless, the high success rate and low donor risk may justify this option for pediatric patients, as well as for a limited population of adult patients suffering from FHF or SFHF.

Entities:  

Mesh:

Year:  1999        PMID: 10573533     DOI: 10.1002/hep.510300621

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

Review 1.  Recent advances in pediatric liver transplantation.

Authors:  Debora Kogan-Liberman; Sukru Emre; Benjamin L Shneider
Journal:  Curr Gastroenterol Rep       Date:  2002-02

Review 2.  Liver transplantation for fulminant hepatic failure.

Authors:  David H Van Thiel; John Brems; Abdul Nadir; Ramazan Idilman; Alessandra Colantoni; David Holt; Steven Edelstein
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

3.  Effect of artificial liver support system on patients with severe viral hepatitis: a study of four hundred cases.

Authors:  Lan-Juan Li; Qian Yang; Jian-Rong Huang; Xiao-Wei Xu; Yue-Mei Chen; Su-Zhen Fu
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

Review 4.  Management in acute liver failure.

Authors:  Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2014-12-03

5.  Adult-to-adult Right Hepatic Lobe Living Donor Liver Transplantation.

Authors:  James F. Trotter
Journal:  Curr Treat Options Gastroenterol       Date:  2002-12

6.  Outcomes of living versus deceased donor liver transplantation for acute liver failure in the United States.

Authors:  N H Urrunaga; V P Rachakonda; L S Magder; A L Mindikoglu
Journal:  Transplant Proc       Date:  2014 Jan-Feb       Impact factor: 1.066

Review 7.  Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortages.

Authors:  M I Prince; M Hudson
Journal:  Postgrad Med J       Date:  2002-03       Impact factor: 2.401

Review 8.  Acute liver failure and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2013-08

Review 9.  Etiology and management of fulminant hepatic failure.

Authors:  Javier Vaquero; Andres T Blei
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 10.  Acute liver failure.

Authors:  Ludwig Kramer
Journal:  Wien Klin Wochenschr       Date:  2004-02-16       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.